Are all adverse effects undesirable? a case of chemotherapy induced adverse effect- an exception!?

D. Malathi, R. Priyadharsini, D. Elango
{"title":"Are all adverse effects undesirable? a case of chemotherapy induced adverse effect- an exception!?","authors":"D. Malathi, R. Priyadharsini, D. Elango","doi":"10.18203/2319-2003.ijbcp20214122","DOIUrl":null,"url":null,"abstract":"Targeted cancer therapies, a recent development in cancer chemotherapy are drugs that block the growth and spread of cancer by interfering with specific molecules which are responsible for the progression of cancer, among which tyrosine kinase inhibitors play an important role. Erlotinib is a tyrosine kinase inhibitor that targets the epidermal growth factor receptor and is a promising drug for the treatment of non-small cell lung cancers and unresectable metastatic pancreatic cancers. Adverse drug reactions are noxious and unintended responses to drugs that occur at doses normally used in man. Cancer chemotherapeutics are well known to cause a wide range of adverse effects from mild to serious ones. All anticancer drugs cause alopecia, gastrointestinal disturbances, skin and hair changes as they affect all the rapidly proliferating cells in addition to cancer cells. Erlotinib causes some less serious adverse effects, one of which is trichomegaly which is presented here in this case report. Though adverse reactions are generally undesirable, trichomegaly induced by erlotinib could be considered as a marker of good tumor response to treatment and a positive outcome. Moreover, this adverse effect could be exploited in the treatment of madarosis for which currently, treatment options are very few.","PeriodicalId":13901,"journal":{"name":"International Journal of Basic & Clinical Pharmacology","volume":"18 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Basic & Clinical Pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18203/2319-2003.ijbcp20214122","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Targeted cancer therapies, a recent development in cancer chemotherapy are drugs that block the growth and spread of cancer by interfering with specific molecules which are responsible for the progression of cancer, among which tyrosine kinase inhibitors play an important role. Erlotinib is a tyrosine kinase inhibitor that targets the epidermal growth factor receptor and is a promising drug for the treatment of non-small cell lung cancers and unresectable metastatic pancreatic cancers. Adverse drug reactions are noxious and unintended responses to drugs that occur at doses normally used in man. Cancer chemotherapeutics are well known to cause a wide range of adverse effects from mild to serious ones. All anticancer drugs cause alopecia, gastrointestinal disturbances, skin and hair changes as they affect all the rapidly proliferating cells in addition to cancer cells. Erlotinib causes some less serious adverse effects, one of which is trichomegaly which is presented here in this case report. Though adverse reactions are generally undesirable, trichomegaly induced by erlotinib could be considered as a marker of good tumor response to treatment and a positive outcome. Moreover, this adverse effect could be exploited in the treatment of madarosis for which currently, treatment options are very few.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
是否所有的副作用都是不可取的?1例化疗引起的不良反应-例外!?
靶向癌症治疗是癌症化疗领域的一项新发展,它是通过干扰与癌症进展有关的特定分子来阻止癌症生长和扩散的药物,其中酪氨酸激酶抑制剂起着重要作用。厄洛替尼是一种酪氨酸激酶抑制剂,靶向表皮生长因子受体,是治疗非小细胞肺癌和不可切除转移性胰腺癌的有希望的药物。药物不良反应是对人体正常使用剂量的药物产生的有害和意外反应。众所周知,癌症化疗药物会引起从轻微到严重的各种不良反应。所有的抗癌药物都会导致脱发、胃肠道紊乱、皮肤和头发的变化,因为它们除了影响癌细胞外,还会影响所有快速增殖的细胞。厄洛替尼引起一些不太严重的副作用,其中之一是滴虫症,这是在这个病例报告中提出的。虽然不良反应通常是不希望发生的,但厄洛替尼诱导的滴虫性可以被认为是肿瘤对治疗有良好反应和积极结果的标志。此外,这种不利影响可用于治疗骨质疏松症,目前,治疗方案很少。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Current status of calcitonin gene-related peptide-based therapies in migraine: a scoping review Efficacy of current treatments against hepatitis C virus Adverse drug reactions to first line anti-tuberculosis drugs in newly diagnosed tuberculosis patients Comparing the effect of statins on hepatic fibrosis induced by carbon tetrachloride in Wistar rats Prescription audit of antihypertensive drugs used in stroke patients in a tertiary care teaching hospital
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1